Phosphodiesterase‐5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study
Aging Cell · 2025
DOI: 10.1111/acel.70265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2025. Verfasst von Marta Alcalde-Herraiz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Alzheimer Disease, Mendelian Randomization Analysis, Phosphodiesterase 5 Inhibitors, Cyclic Nucleotide Phosphodiesterases, Type 5. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre.
Themen: Demenz
Abstract (Originalsprache)
While preclinical studies suggest that Phosphodiesterase 5 (PDE5) inhibition may reduce cognitive impairment, findings from observational studies on whether PDE5 inhibitors reduce Alzheimer's disease (AD) risk have been inconsistent. We performed a two‐sample cis ‐Mendelian Randomisation (MR) analysis to estimate the causal effect of PDE5 inhibition on AD risk. The analysis was performed across four different genome‐wide association studies (GWAS) of AD to enhance reliability through triangulation. Additionally, a sex‐stratified MR analysis using data from UK Biobank was performed to assess potential sex‐specific effects. No evidence of a causal association between PDE5 inhibition and AD risk was found in the main analyses. Similar findings were obtained in the sex‐stratified analysis. Our study uses genetic data to triangulate the evidence and suggests that PDE5 inhibitors are unlikely to decrease the risk of AD. Further research is needed to thoroughly understand the impact of PDE5 inhibitors on the risk of Alzheimer's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.
- School of Psychological Science, University of Bristol, Bristol, UK.
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
- Division of Psychiatry, University College of London, London, UK.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
ORCID-Profile: Marta Alcalde-Herraiz, Daniel Prieto-Alhambra, Danielle Newby
Förderung
- NIHR Oxford Biomedical Research Centre
Zitieren
APA
Alcalde-Herraiz, M., Woolf, B., Xie, J., Anderson, E., Gill, D., Tzoulaki, I., Winchester, L. M., Yarmolinsky, J., Prieto-Alhambra, D., & Newby, D. (2025). Phosphodiesterase‐5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study. Aging Cell. https://doi.org/10.1111/acel.70265
Vancouver
Alcalde-Herraiz M, Woolf B, Xie J, Anderson E, Gill D, Tzoulaki I, et al. Phosphodiesterase‐5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study. Aging Cell. 2025. doi:10.1111/acel.70265
BibTeX
@article{AlcaldeHerraiz2025,
author = {Alcalde-Herraiz, Marta and Woolf, Benjamin and Xie, Junqing and Anderson, Emma and Gill, Dipender and Tzoulaki, Ioanna and Winchester, Laura M and Yarmolinsky, James and Prieto-Alhambra, Daniel and Newby, Danielle},
title = {Phosphodiesterase‐5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70265}
}
EUVIMED